Excelsior Biopharma (ROCO:6496) Total Equity: NT$689.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6496 Excelsior Biopharma Inc ROCO:6496
58 GF Score
Price NT$24.90
GF Value NT$33.83
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Excelsior Biopharma Total Equity?

Excelsior Biopharma ROCO:6496 +1.63% 58 Total Equity is NT$689.0 Mil as of Jun. 2026. GuruFocus rates ROCO:6496 with a GF Score™ of 58/100 and a GF Value™ of NT$33.83 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Excelsior Biopharma's total equity for the quarter that ended in Jun. 2026 was NT$689.0 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Excelsior Biopharma Total Equity Historical Data

* Premium members only.

The historical data trend for Excelsior Biopharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Excelsior Biopharma Total Equity Chart

Excelsior Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,230.15 1,207.44 1,104.45 991.45 804.23

Excelsior Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 896.79 846.79 804.23 745.84 688.99
ROCO:6496
58GF Score
Excelsior Biopharma Inc ROCO:6496
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Excelsior Biopharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Excelsior Biopharma's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1484.013-679.781
=804.2

Excelsior Biopharma's Total Equity for the quarter that ended in Jun. 2026 is calculated as

Total Equity=Total Assets(Q: Jun. 2026 )-Total Liabilities(Q: Jun. 2026 )
=1417.786-728.8
=689.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$689.0 Mil mean?
Excelsior Biopharma (ROCO:6496) has a Total Equity of NT$689.0 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Excelsior Biopharma and its competitors.
Is Excelsior Biopharma's Total Equity too high?
Excelsior Biopharma's current Total Equity is NT$689.0 Mil. Overall, Excelsior Biopharma has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Excelsior Biopharma's Total Equity compare to ZTS?
Excelsior Biopharma's Total Equity of NT$689.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Excelsior Biopharma and its competitors. Excelsior Biopharma's current Total Equity is NT$689.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Excelsior Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Excelsior Biopharma (ROCO:6496) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.83, compared to a current price of NT$24.90 — trading 26.4% below its estimated fair value. The current Total Equity is NT$689.0 Mil. Excelsior Biopharma's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Excelsior Biopharma (ROCO:6496), the current Total Equity is NT$689.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Excelsior Biopharma (ROCO:6496) Overvalued in 2026?

Based on GuruFocus' analysis, Excelsior Biopharma stock appears to be undervalued. The current stock price of NT$24.90 is trading 26.4% below its estimated GF Value™ of NT$33.83. GuruFocus considers Excelsior Biopharma to be Modestly Undervalued.

Key valuation signals for ROCO:6496:

  • Total Equity: NT$689.0 Mil
  • GF Value™: NT$33.83 vs. price of NT$24.90 (26.4% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6496 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Excelsior Biopharma Business Description

Address Zhongxiao E. Road, 5Floor, No.508, Sector 7, Nangang District, Taipei, TWN, 11561
Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, food, cosmecteuticals and development of cosmetics, research, importing, and exporting of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.
58GF Score

Get the complete analysis for ROCO:6496

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.90
Price
NT$33.83
GF Value